文献速递造血干细胞移植与细胞治疗

泊索鲁塞在异基因造血细胞移植受者中的2期试验最终结局

Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.
PubMed 文献 · Blood Adv · 2024-01-01

这项开放标签2期试验在高危异基因造血细胞移植受者中评估泊索鲁塞预防6种目标病毒临床显著感染的安全性和感染率。26例患者中仅3例(12%)在第14周前发生临床显著感染,重复给药总体安全且耐受良好,并与功能性免疫重建相关。

要点

  • 高危异基因造血细胞移植受者接受泊索鲁塞后第14周临床显著感染率为12%(3/26)。
  • 5例(19%)发生2至4级急性移植物抗宿主病,无患者发生细胞因子释放综合征。
  • 经干扰素-γ酶联免疫斑点试验检测的病毒特异性T细胞体内扩增与病毒控制相关。

核心结论

  • 接受泊索鲁塞的高危异基因造血细胞移植受者6种目标病毒所致临床显著感染率低,重复给药总体安全且耐受良好,并与功能性免疫重建相关。

研究设计与样本

  • 开放标签2期试验,纳入基于脐带血、单倍体、错配或相合无关供者移植,或移植后淋巴细胞<180/mm3,或使用T细胞去除的高危异基因造血细胞移植受者,共26例。
  • 泊索鲁塞在异基因造血细胞移植后15至49天内开始给药,随后每14天一次,最多7剂。
  • 主要终点为第14周前由6种目标病毒(腺病毒、BK病毒、巨细胞病毒、EB病毒、人类疱疹病毒6型或JC病毒)所致的临床显著感染数。

主要发现

  • 26例患者中仅3例(12%)在第14周前发生临床显著感染,每例均为单一目标病毒。
  • 通过干扰素-γ酶联免疫斑点试验检测的功能性病毒特异性T细胞体内扩增与病毒控制相关。
  • T细胞受体深度测序证实泊索鲁塞来源的T细胞克隆在末次输注后持续长达14周。
  • 5例(19%)发生2至4级急性移植物抗宿主病,无患者发生细胞因子释放综合征。
  • 全部6例死亡均归因于复发或疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (allo-HCT) recipients are susceptible to viral infections. We conducted a phase 2 trial evaluating the safety and rate of clinically significant infections (CSIs; viremia requiring treatment or end-organ disease) after infusion of posoleucel, a partially HLA-matched, allogeneic, off-the-shelf, multivirus-specific T-cell investigational product for preventing CSIs with adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, or JC virus. This open-label trial enrolled allo-HCT recipients at high risk based on receiving grafts from umbilical cord blood, haploidentical, mismatched, or matched unrelated donors; post-HCT lymphocytes of <180/mm3; or use of T-cell depletion. Posoleucel dosing was initiated within 15 to 49 days of allo-HCT and subsequently every 14 days for up to 7 doses. The primary end point was the number of CSIs due to the 6 target viruses by week 14. Of the 26 patients enrolled, only 3 (12%) had a CSI by week 14, each with a single target virus. In vivo expansion of functional virus-specific T cells detected via interferon-γ enzyme-linked immunosorbent spot assay was associated with viral control. Persistence of posoleucel-derived T-cell clones for up to 14 weeks after the last infusion was confirmed by T-cell-receptor deep sequencing. Five patients (19%) had acute graft-versus-host disease grade 2 to 4. No patient experienced cytokine release syndrome. All 6 deaths were due to relapse or disease progression. allo-HCT recipients at high risk who received posoleucel had low rates of CSIs from 6 targeted viruses. Repeat posoleucel dosing was generally safe and well tolerated and associated with functional immune reconstitution. This trial was registered at www.ClinicalTrials.gov as #NCT04693637.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dadwal SS, Bansal R, Schuster MW, et al. Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients. Blood Adv. 2024. PMID: 38593233. doi:10.1182/bloodadvances.2023011562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。